Books and Book Chapters

      Genetic Markers in Tobacco, Usage for Map Development, Diversity Studies, and Quantitative Trait Loci Analysis

      Bakaher, N.

      Date published
      Mar 17, 2020
      DOI
      10.1007/978-3-030-29493-9_3
      ISBN
      978-3-030-29493-9
      Published in
      The Tobacco Plant Genome
      Editors
      Ivanov, N. V.; Sierro, N.; Peitsch, M. C.
      Link to publication
      Topic
      Summary

      Tobacco (Nicotiana tabacum L.) is an allotetraploid species in the Solanaceae family and has a complex genome. The first genetic maps of tobacco have been developed using microsatellite markers. Microsatellite markers were also used to create links between genetic maps of various Nicotiana species, providing a platform for synteny analysis. Markers are also an efficient tool to decipher the population genetics of tobacco. The three main tobacco types used in smoking products are flue-cured or Virginia, Burley, and Oriental. The commercial type is translated in genetic divergence resulting from the selection of adapted cultivars associated with agronomical and curing crop practices. Genetic markers are needed for trait discovery via quantitative trait locus mapping. They were used to identify loci involved in leaf surface components (cis-abienol and sucrose esters) and contributing to flavor and aroma characteristics. Another QTL mapping study targeting resistance to soilborne diseases such as black shank and bacterial wilt led to the identification of several loci that provide a better understanding of polygenic disease resistance in tobacco. Today with the availability of the genome sequence, single-nucleotide polymorphisms are being developed in tobacco. They are a fast, reproducible, and cost-efficient screening method for any genetic application from basic research to commercial breeding that may accelerate the pace of discoveries in tobacco.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.